From pathogenesis to novel therapies in the treatment of primary biliary cholangitis-Reference-Cited by-同舟云学术

From pathogenesis to novel therapies in the treatment of primary biliary cholangitis

Published:2017-11-09 Issue:12 Volume:13 Page:1121-1131
ISSN:1744-666X
Container-title:Expert Review of Clinical Immunology
language:en
Short-container-title:Expert Review of Clinical Immunology

Author:

Ronca Vincenzo¹²^ORCID,Carbone Marco²,Bernuzzi Francesca²,Malinverno Federica²,Mousa Hani S.³^ORCID,Gershwin M. Eric⁴,Invernizzi Pietro²⁴^ORCID

Affiliation:

1. Department of Medicine, S. Paolo Hospital, University of Milan, Milan, Italy

2. Program for Autoimmune Liver Diseases, International Center for Digestive Health, Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy

3. School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, CB2 0AH, United Kingdom

4. Division of Rheumatology, Allergy, and Clinical Immunology, University of California at Davis, Davis, CA, USA

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2017.1391093

Reference118 articles.

1. Changing nomenclature for PBC: From ‘cirrhosis’ to ‘cholangitis’

2. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis

3. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

4. Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis

5. Sex and Age Are Determinants of the Clinical Phenotype of Primary Biliary Cirrhosis and Response to Ursodeoxycholic Acid

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The emerging significance of mitochondrial targeted strategies in NAFLD treatment;Life Sciences;2023-09

2. Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government;Applied Health Economics and Health Policy;2023-07-03

3. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease;Acta Pharmacologica Sinica;2022-02-25

4. Use of immunosuppression in non-transplant hepatology;Best Practice & Research Clinical Gastroenterology;2021-10

5. Gut-Liver Immune Traffic: Deciphering Immune-Pathogenesis to Underpin Translational Therapy;Frontiers in Immunology;2021-08-25